Business Valuation: Packaging (Medical / Pharma)

The average Swiss Packaging (Medical / Pharma) company is valued at 5.5 - 7.5× EBITDA on a statutory (tax-based) basis and 6.5 - 9.5× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is rising, with an arbitrage gap rated as medium. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

Key valuation drivers include: Qualification and revalidation costs make incumbent suppliers exceptionally hard to displace; Adjacency to one of the world’s densest pharma and medtech clusters — Swiss OEMs on the doorstep. Factors that can compress valuations include: The wider packaging base is shrinking — combined NOGA 22+17 employment down 18.2% since 2012 (BFS STATENT 2024); Paper and board is contracting sharply at -32.3% employment since 2012, squeezing carton-based converters. Deal multiples typically range from 6.5 - 9.5× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

Medical and pharmaceutical packaging sits inside two official divisions: plastics and rubber products (NOGA 22) and paper and board products (NOGA 17). BFS STATENT 2024, published in August 2026, counts 897 establishments across the two for the 2024 reference year, employing 27,606 people or 25,535 full-time equivalents. Both have contracted since 2012 — combined employment down 18.2% and establishments down 13.7%, with paper and board falling hardest at -32.3% employment. The dedicated medical and pharmaceutical segment within that base is estimated at around CHF 4.8 billion and is holding up far better than the commodity packaging around it, because a validated component cannot be replaced by a cheaper one without regulatory revalidation.

Medical packaging companies in Switzerland command premium valuations (5.5-7.5× statutory, 6.5-9.5× deal multiples) due to their embedded position in pharma supply chains and high regulatory barriers. Customer switching costs are significant: revalidating a packaging supplier takes 12-18 months and costs CHF 200K-500K per product. This creates sticky revenue streams and makes well-run packaging firms highly attractive acquisition targets for private equity and strategic buyers. The consolidation trend is accelerating, with DS Smith acquiring Model AG and strategic buyers like Körber acquiring Dividella. Deal multiples for the sector typically run 6.5 - 9.5× EBITDA.

Five trends define the sector in 2026: (1) Consumables Compound, Capital Equipment Cycles — The two listed Swiss names moved in opposite directions in 2025 and the split is structural, not idiosyncratic. (2) US Pharma Tariffs Reach the Packaging Chain — Pharmaceutical tariffs of up to 15% took effect on 31 July 2026, on top of the broader Section 301 duties of up to 12.5% applied from 24 July 2026 and the Section 122 baseline before them. (3) The Base Is Shrinking, the Qualified Niche Is Not — BFS STATENT 2024 shows the divisions containing medical packaging contracting hard: plastics and rubber products employment down 12.9% since 2012, paper and board down 32.3%, and 897 establishments left across both against 1,039 in 2012. (4) Injectables Pull Structural Volume — Biologics, biosimilars and GLP-1 therapies are shifting drug delivery toward prefilled syringes, cartridges and autoinjectors — every one of which needs elastomer closures, barrier films and validated secondary packaging. (5) Requalification Windows Are the Only Way In — Switching costs cut both ways. Incumbency is durable because revalidation is expensive, but that same mechanism means the only realistic entry points are moments when the customer must requalify anyway — a sustainability-driven material change, a GMP annex revision, a serialisation upgrade, or a site transfer.

The principal acquisition risks are: (1) US pharmaceutical tariffs of up to 15% took effect on 31 July 2026, directly exposing the pharma value chain (SECO); (2) Broader US tariff regime: Section 301 duties of up to 12.5% since 24 July 2026, after the 39% shock of August 2025; (3) Customer concentration risk — a small number of large pharma OEMs dominate qualified demand. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 6.5 - 9.5× EBITDA may be discounted for firms with elevated risk profiles.

The typical cost breakdown for a Swiss Packaging (Medical / Pharma) firm is: Materials (plastics, foils, paper, closures): 35%, Personnel Costs (incl. GMP-trained operators): 30%, Cleanroom & Equipment Depreciation: 10%, Quality & Regulatory Compliance: 7%, Other Operating Costs: 8%, Profit Margin (EBITDA): 10%. Pharma packaging commands higher margins than general packaging due to regulatory barriers and quality requirements. Cleanroom operations add ~20% to operating costs vs. standard packaging. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

Switzerland's main Packaging (Medical / Pharma) clusters are: (1) Basel Region (BS, BL, AG) — The pharma capital of Switzerland. Novartis, Roche HQs drive enormous packaging demand. (2) Bern & Fribourg (BE, FR) — Ypsomed (Burgdorf), Medistri (Domdidier). Strong in drug delivery devices and sterile packaging. (3) Eastern Switzerland (SH, TG, SG) — SIG Group HQ (Neuhausen), Dividella (Grabs), Model AG (Weinfelden). (4) Zurich Region (ZH) — Wipf AG (Volketswil). Hub for packaging design, marketing, and distribution. Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.